Moleculin Biotech, Inc. — Q2 2019 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2019. Moleculin is a clinical-stage oncology drug developer with no product revenue. Its three clinical-stage candidates were being studied across four trials in the U.S. and Poland.
Financial performance and position
| Metric | Q2 2019 | Six months 2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $2.10 million | $5.03 million |
| General and administrative expense | $1.48 million | $3.08 million |
| Operating loss | $3.63 million | $8.20 million |
| Net loss | $1.22 million | $5.26 million |
| Net loss per share, basic and diluted | $0.03 | $0.15 |
| Operating cash used | Not separately stated | $9.19 million |
At June 30, cash and cash equivalents were $18.70 million, total current assets $20.20 million, current liabilities $9.59 million, total liabilities $9.76 million, and stockholders’ equity $22.09 million. The company reported no conventional borrowings; it had $206,000 in present-value operating lease liabilities. Warrant liabilities were $6.94 million, measured using Level 3 fair-value inputs.
Cash increased $11.56 million during the six months, primarily because $20.80 million of financing cash flow—including March and April stock-and-warrant offerings and warrant exercises—exceeded operating cash use. The company issued 16.67 million net additional common shares from year-end to June 30; 45.20 million shares were outstanding at June 30.
Changes versus prior comparable periods
- Q2 net loss narrowed from $5.13 million in 2018 to $1.22 million in 2019; six-month net loss narrowed from $7.05 million to $5.26 million.
- Q2 R&D expense fell by $2.13 million, mainly because the prior-year quarter included costs to produce additional Annamycin clinical-trial drug product. Six-month R&D declined by $0.44 million despite increased clinical activity and headcount.
- G&A expense rose $0.26 million for Q2 and $0.46 million for the six-month period, mainly due to payroll and, year to date, stock-based compensation.
- Operating cash use increased from $6.27 million to $9.19 million for the first six months, reflecting drug development, manufacturing and testing, staffing, sponsored research and license costs.
- Reported results benefited from noncash gains on warrant remeasurement: $2.41 million in Q2 and $2.94 million for six months, versus $0.33 million and $1.04 million in 2018. The gains are sensitive to the company’s share price and warrant valuation assumptions.
Outlook, developments and key risks
- Management estimated that June 30 cash would fund planned operations into the second quarter of 2020 without further equity financing. It also stated that additional capital would be needed to fund future operations and that failure to obtain funding could force program delays, reductions or cessation. The financial statements identify substantial doubt about the company’s ability to continue as a going concern.
- No formal revenue or earnings guidance was provided. Management expected to submit a U.S. IND for WP1732 in 2020; WP1122 remained in preclinical development. The company also entered a new ATM agreement in July permitting up to $15 million in share sales; no shares had been sold under it as of the filing.
- Annamycin was in Phase I/II trials for relapsed or refractory AML in the U.S. and Poland. Management reported preliminary safety and efficacy observations, including no reported cardiotoxicity to date, but cautioned that results were early and recruitment could be slow or delayed. FDA Fast Track designation for Annamycin was announced in April 2019.
- WP1066 was in a physician-sponsored Phase I brain-tumor trial; WP1220 was being studied for cutaneous T-cell lymphoma. After quarter-end, the company announced WP1220 trial enrollment was complete. These programs remain experimental, and successful development, regulatory approval and commercialization are uncertain.
- Key risks include reliance on future financing, clinical-trial enrollment and outcomes, regulatory approvals, third-party manufacturers and collaborators, and licensed intellectual property. Annamycin’s drug substance lacked existing patent protection; new formulation, process and reconstitution patent applications had been filed, with no assurance they would be granted.
- Disclosure controls were deemed ineffective due to a material weakness in segregation of accounting duties. Management reported remedial steps and additional review procedures, but the weakness had not been stated as remediated.
- Post-quarter developments included a July modification of a sublicense that narrowed a territory and contemplated issuing shares valued at $0.5 million, and an August warrant issued to a consultant. The filing also describes affiliated sublicense partners and related-party considerations.
Most important facts for investors to verify
- Cash runway assumptions, quarterly cash burn and the extent of future financing needs; assess dilution from the ATM, warrants and other equity issuance.
- Warrant liability valuation and its noncash effect on reported earnings, including sensitivity to share-price changes.
- Updated trial enrollment, safety, efficacy and dose-escalation data for Annamycin, WP1066 and WP1220; distinguish preliminary company-reported findings from established clinical benefit.
- Whether the accounting segregation-of-duties material weakness is remediated and whether disclosure controls become effective.
- Terms, governance and development progress of affiliated sublicenses, including any related-party transactions and potential future royalty revenue.